Quest PharmaTech Inc (QPT) - Total Assets
Based on the latest financial reports, Quest PharmaTech Inc (QPT) holds total assets worth CA$24.33 Million CAD (≈ $17.60 Million USD) as of October 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Quest PharmaTech Inc - Total Assets Trend (1998–2025)
This chart illustrates how Quest PharmaTech Inc's total assets have evolved over time, based on quarterly financial data. Also see Quest PharmaTech Inc market capitalisation for the company's overall valuation and market capitalisation.
Quest PharmaTech Inc - Asset Composition Analysis
Current Asset Composition (January 2025)
Quest PharmaTech Inc's total assets of CA$24.33 Million consist of 1.0% current assets and 99.0% non-current assets. Review QPT liabilities breakdown to assess the company's total debt and financial obligations.
| Asset Category | Amount (CAD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 0.9% |
| Accounts Receivable | CA$0.00 | 0.0% |
| Inventory | CA$0.00 | 0.0% |
| Property, Plant & Equipment | CA$0.00 | 0.0% |
| Intangible Assets | CA$0.00 | 0.0% |
| Goodwill | CA$0.00 | 0.0% |
Asset Composition Trend (1998–2025)
This chart illustrates how Quest PharmaTech Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See current stock price of Quest PharmaTech Inc for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Quest PharmaTech Inc's current assets represent 1.0% of total assets in 2025, a decrease from 100.0% in 1998.
- Cash Position: Cash and equivalents constituted 0.9% of total assets in 2025, down from 98.4% in 1998.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1998.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Quest PharmaTech Inc Competitors by Total Assets
Key competitors of Quest PharmaTech Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Quest PharmaTech Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.07 | 0.31 | 1.13 |
| Quick Ratio | 0.07 | 0.31 | 1.13 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CA$-1.17 Million | CA$-742.53K | CA$35.86K |
Quest PharmaTech Inc - Advanced Valuation Insights
This section examines the relationship between Quest PharmaTech Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.22 |
| Latest Market Cap to Assets Ratio | 0.11 |
| Asset Growth Rate (YoY) | -7.8% |
| Total Assets | CA$22.56 Million |
| Market Capitalization | $2.45 Million USD |
Valuation Analysis
Below Book Valuation: The market values Quest PharmaTech Inc's assets below their book value (0.11x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Quest PharmaTech Inc's assets decreased by 7.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Quest PharmaTech Inc (1998–2025)
The table below shows the annual total assets of Quest PharmaTech Inc from 1998 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-01-31 | CA$22.56 Million ≈ $16.32 Million |
-7.81% |
| 2024-01-31 | CA$24.48 Million ≈ $17.71 Million |
-70.99% |
| 2023-01-31 | CA$84.36 Million ≈ $61.02 Million |
-7.33% |
| 2022-01-31 | CA$91.03 Million ≈ $65.85 Million |
-48.17% |
| 2021-01-31 | CA$175.61 Million ≈ $127.04 Million |
+3844.78% |
| 2020-01-31 | CA$4.45 Million ≈ $3.22 Million |
-23.38% |
| 2019-01-31 | CA$5.81 Million ≈ $4.20 Million |
-54.56% |
| 2018-01-31 | CA$12.78 Million ≈ $9.25 Million |
+12.48% |
| 2017-01-31 | CA$11.37 Million ≈ $8.22 Million |
+4.54% |
| 2016-01-31 | CA$10.87 Million ≈ $7.87 Million |
+3174.98% |
| 2015-01-31 | CA$331.99K ≈ $240.16K |
-63.19% |
| 2014-01-31 | CA$901.85K ≈ $652.39K |
+176.43% |
| 1998-01-31 | CA$326.25K ≈ $236.01K |
-- |
About Quest PharmaTech Inc
Quest PharmaTech Inc., a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. The company's lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16 for the potential cancer targets, including pancreatic, colon, leukemia, ovarian, and breast cancer. Quest PharmaTech Inc. is headquartered in Edmonton, Canada.